Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine
KRAS is one of the most highly mutated oncoproteins, which is overexpressed in various human cancers and implicated in poor survival. The G-quadruplex formed in KRAS oncogene promoter ( KRAS -G4) is a transcriptional modulator and amenable to small molecule targeting. However, no available KRAS -G4-...
Gespeichert in:
Veröffentlicht in: | Nature communications 2022-10, Vol.13 (1), p.6016-6016, Article 6016 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | KRAS is one of the most highly mutated oncoproteins, which is overexpressed in various human cancers and implicated in poor survival. The G-quadruplex formed in
KRAS
oncogene promoter (
KRAS
-G4) is a transcriptional modulator and amenable to small molecule targeting. However, no available
KRAS
-G4-ligand complex structure has yet been determined, which seriously hinders the structure-based rational design of
KRAS
-G4 targeting drugs. In this study, we report the NMR solution structures of a bulge-containing
KRAS
-G4 bound to berberine and coptisine, respectively. The determined complex structure shows a 2:1 binding stoichiometry with each compound recruiting the adjacent flacking adenine residue to form a “quasi-triad plane” that stacks over the two external G-tetrads. The binding involves both
π
-stacking and electrostatic interactions. Moreover, berberine and coptisine significantly lowered the
KRAS
mRNA levels in cancer cells. Our study thus provides molecular details of ligand interactions with
KRAS
-G4 and is beneficial for the design of specific
KRAS
-G4-interactive drugs.
The G-quadruplex formed in KRAS oncogene promoter (KRAS-G4) is a transcriptional modulator and amenable to small molecule targeting. Herein, the authors report the NMR solution structures of a bulge-containing KRAS-G4 that bound to two small molecules. The study provides molecular details of ligand interactions with KRAS-G4 and contributes insight into the design of specific KRAS-G4-interactive drugs. |
---|---|
ISSN: | 2041-1723 2041-1723 |
DOI: | 10.1038/s41467-022-33761-4 |